Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* male or female patients, 12-75 years of age;~* diagnosis of systemic lupus erythematosus;~* kidney biopsy within 6 months of study, with histological diagnosis of lupus nephritis;~* laboratory evidence of active nephritis.~Exclusion Criteria:~* continuous dialysis starting \>2 weeks before randomization into induction phase, and/or with an anticipated duration of \>8 weeks;~* previous or planned kidney transplant;~* other clinically significant active medical conditions.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Induction Phase: Mycophenolate mofetil (Type: EXPERIMENTAL): Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24 weeks of the Induction Phase.
- Induction Phase: Cyclophosphamide (Type: ACTIVE_COMPARATOR): Participants received monthly infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.
- Maintenance Phase: Mycophenolate mofetil (Type: EXPERIMENTAL): Participants received mycophenolate mofetil (MMF) 1.0 g orally twice a day, placebo to azathioprine orally once a day and corticosteroid for the 36 weeks Maintenance Phase.
- Maintenance Phase: Azathioprine (Type: ACTIVE_COMPARATOR): Participants received azathioprine (AZA) 2 mg/kg/day orally once a day, placebo to mycophenolate mofetil orally twice a day and corticosteroid for the 36 weeks Maintenance Phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).